Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

Chronic kidney disease; Dialysis; Immunotherapy

Detalhes bibliográficos
Autores: Bermejo Garcia, Sheila, Bolufer Cardona, Monica, Riveiro Barciela, Maria del Mar, Soler Romeo, Maria Jose
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2022
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/8175
Acesso em linha:https://hdl.handle.net/11351/8175
http://hdl.handle.net/11351/8175
Access Level:Acceso aberto
Palavra-chave:Immunotoxicologia
Medicaments - Toxicologia
Nefrotoxicologia
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Nephritis, Interstitial
Other subheadings::Other subheadings::Other subheadings::/chemically induced
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::nefritis intersticial
Otros calificadores::Otros calificadores::Otros calificadores::/inducido químicamente
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
id ES_cbb3e4b3e34d6521c7e01213cfd187e3
oai_identifier_str oai:recercat.cat:11351/8175
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
title Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
spellingShingle Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
Bermejo Garcia, Sheila
Immunotoxicologia
Medicaments - Toxicologia
Nefrotoxicologia
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Nephritis, Interstitial
Other subheadings::Other subheadings::Other subheadings::/chemically induced
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::nefritis intersticial
Otros calificadores::Otros calificadores::Otros calificadores::/inducido químicamente
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
title_short Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
title_full Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
title_fullStr Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
title_full_unstemmed Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
title_sort Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
dc.creator.none.fl_str_mv Bermejo Garcia, Sheila
Bolufer Cardona, Monica
Riveiro Barciela, Maria del Mar
Soler Romeo, Maria Jose
author Bermejo Garcia, Sheila
author_facet Bermejo Garcia, Sheila
Bolufer Cardona, Monica
Riveiro Barciela, Maria del Mar
Soler Romeo, Maria Jose
author_role author
author2 Bolufer Cardona, Monica
Riveiro Barciela, Maria del Mar
Soler Romeo, Maria Jose
author2_role author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Bermejo S, Bolufer M, Soler MJ] Servei de Nefrologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Barcelona, Spain. [Riveiro-Barciela M] Unitat Hepàtica, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Immunotoxicologia
Medicaments - Toxicologia
Nefrotoxicologia
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Nephritis, Interstitial
Other subheadings::Other subheadings::Other subheadings::/chemically induced
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::nefritis intersticial
Otros calificadores::Otros calificadores::Otros calificadores::/inducido químicamente
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
topic Immunotoxicologia
Medicaments - Toxicologia
Nefrotoxicologia
DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Nephritis, Interstitial
Other subheadings::Other subheadings::Other subheadings::/chemically induced
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::nefritis intersticial
Otros calificadores::Otros calificadores::Otros calificadores::/inducido químicamente
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
description Chronic kidney disease; Dialysis; Immunotherapy
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/8175
http://hdl.handle.net/11351/8175
url https://hdl.handle.net/11351/8175
http://hdl.handle.net/11351/8175
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Frontiers in Medicine;9
https://doi.org/10.3389/fmed.2022.906565
info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F01292
info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0009%2F0030
info:eu-repo/grantAgreement/ES/PE2017-2020/RD21%2F0005%2F0016
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419611214053376
spelling Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?Bermejo Garcia, SheilaBolufer Cardona, MonicaRiveiro Barciela, Maria del MarSoler Romeo, Maria JoseImmunotoxicologiaMedicaments - ToxicologiaNefrotoxicologiaDISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Nephritis, InterstitialOther subheadings::Other subheadings::Other subheadings::/chemically inducedCHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, ImmunologicalOther subheadings::Other subheadings::Other subheadings::/adverse effectsENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::nefritis intersticialOtros calificadores::Otros calificadores::Otros calificadores::/inducido químicamenteCOMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásicaOtros calificadores::Otros calificadores::Otros calificadores::/efectos adversosChronic kidney disease; Dialysis; ImmunotherapyEnfermedad renal cronica; Diálisis; InmunoterapiaMalaltia renal crònica; Diàlisi; ImmunoteràpiaThe new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases.This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.Frontiers MediaInstitut Català de la Salut[Bermejo S, Bolufer M, Soler MJ] Servei de Nefrologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Barcelona, Spain. [Riveiro-Barciela M] Unitat Hepàtica, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/8175http://hdl.handle.net/11351/8175Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésFrontiers in Medicine;9https://doi.org/10.3389/fmed.2022.906565info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F01292info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0009%2F0030info:eu-repo/grantAgreement/ES/PE2017-2020/RD21%2F0005%2F0016Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/81752026-05-29T05:05:01Z
score 15,198674

Registros relacionados